Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Longevity Health Holdings ( (XAGE) ) has shared an update.
On May 20, 2025, Longevity Health Holdings received approval from the Nasdaq Hearings Panel to continue its listing on Nasdaq, contingent on meeting initial listing requirements following its proposed merger with 20/20 Biolabs by September 2, 2025. The decision follows a strategic plan involving a 1-for-30 reverse stock split and the filing of an S-4 registration statement for the merger, reflecting the company’s efforts to comply with Nasdaq’s rules and advance its mission in the longevity solutions market.
More about Longevity Health Holdings
Longevity Health Holdings, Inc. is a company focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition. The company offers technologies for skin and hair health, including Carmell Secretome and Elevai Exosomes.
Average Trading Volume: 224,623
Technical Sentiment Signal: Sell
Current Market Cap: $3.56M
For detailed information about XAGE stock, go to TipRanks’ Stock Analysis page.